Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26224337
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin
Secretion in Drug-Naïve Patients with Type 2 Diabetes
#MMPMID26224337
Ito R
; Fukui T
; Hayashi T
; Osamura A
; Ohara M
; Hara N
; Higuchi A
; Yamamoto T
; Hirano T
Drugs R D
2015[Sep]; 15
(3
): 245-51
PMID26224337
show ga
INTRODUCTION: It remains unknown whether dipeptidyl peptidase-4 (DPP-4)
inhibitors improve early-phase insulin secretion in Japanese patients with type 2
diabetes (T2D), a disease characterized by impaired insulin secretion. We
investigated the changes in insulin secretion before and after treatment with the
DPP-4 inhibitor teneligliptin in patients with T2D with a low insulinogenic index
(IGI) determined by the oral glucose tolerance test (OGTT). METHODS: An
open-label, prospective clinical study was conducted. Thirteen drug-naïve
patients (mean age 55.5 ± 3.9 years) with T2D underwent OGTT before and after
teneligliptin 20 mg/day monotherapy. Plasma levels of glucose (PG), insulin, and
C-peptide were measured at 0, 30, 60, 90, and 120 min after glucose loading in
the OGTT. Homeostasis model assessment (HOMA)-?, IGI, and the total or
incremental area under the curve (AUC) for PG and insulin were measured.
AUC120min for the secretory units of islets in transplantation (SUIT) index was
also measured. RESULTS: HbA1c significantly decreased from 8.3 ± 0.4% at baseline
to 6.3 ± 0.2% after 12 weeks of teneligliptin treatment (p < 0.05). Incremental
AUC120min PG also significantly decreased, and ?-cell function assessed by
IGI30min, AUC120min insulin, and the AUC120min SUIT index significantly increased
(0.16 ± 0.05 vs. 0.28 ± 0.06, 2692 ± 333 µU·2h/mL vs. 3537 ± 361 µU·2h/mL, and
4261 ± 442 vs. 8290 ± 1147, respectively; all p < 0.05). HOMA-? was unchanged.
The reduction in incremental AUC120min PG was significantly associated with the
augmentation of IGI30min and the AUC120min SUIT index. No severe adverse events
were observed. CONCLUSIONS: Twelve weeks of teneligliptin treatment improved
IGI30min, AUC120min, and the SUIT index in drug-naïve Japanese patients with T2D.
|Adult
[MESH]
|Aged
[MESH]
|Blood Glucose/drug effects
[MESH]
|C-Peptide/blood
[MESH]
|Diabetes Mellitus, Type 2/*drug therapy/*metabolism
[MESH]
|Dipeptidyl-Peptidase IV Inhibitors/pharmacology/*therapeutic use
[MESH]
|Female
[MESH]
|Glucose Tolerance Test
[MESH]
|Humans
[MESH]
|Insulin Secretion
[MESH]
|Insulin-Secreting Cells/drug effects
[MESH]
|Insulin/*metabolism
[MESH]
|Male
[MESH]
|Middle Aged
[MESH]
|Pyrazoles/*pharmacology/*therapeutic use
[MESH]
|Thiazolidines/*pharmacology/*therapeutic use
[MESH]
free
free
free
